Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

NCT03870399 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Progesterone Receptor Positive Tumor
Estrogen Receptor Positive Tumor

Interventions

DRUG: Tamoxifen

Sponsor

AC Camargo Cancer Center

Collaborators

[object Object]